自体培养角膜缘上皮细胞片移植治疗角膜缘干细胞缺乏症的临床试验
这项前瞻性、多中心、开放标签、非对照、单臂临床试验纳入10例单侧角膜缘干细胞缺乏症患者,移植符合药品生产质量管理规范的自体培养角膜缘上皮细胞片,术后1年角膜上皮重建成功率为60%(6/10眼),显著高于异体角膜缘移植的15%临床显著有效率,2年重建率为70%,未观察到临床显著的移植相关不良事件。
要点
- 术后1年角膜上皮重建成功率为60%(6/10眼),显著高于异体角膜缘移植的15%临床显著有效率。
- 术后2年角膜上皮重建率为70%,1年和2年视力改善率分别为50%和60%。
- 未观察到临床显著的移植相关不良事件,细胞片Nepic已在日本获批为细胞和组织制品。
核心结论
- 自体培养角膜缘上皮细胞片移植的有效性和安全性得到确认,该细胞片Nepic已在日本获批为细胞和组织制品。
研究设计与样本
- 前瞻性、多中心、开放标签、非对照、单臂临床试验,纳入10例单侧角膜缘干细胞缺乏症患者的10只连续患眼,术后随访2年。
- 术前角膜缘干细胞缺乏症分期为IIB期4眼、III期6眼,诊断与分期由试验的资格判定委员会和效果评估委员会基于包括荧光素染色的裂隙灯照片确定。
主要发现
- 术后1年角膜上皮重建成功率为60%(6/10眼),显著高于异体角膜缘移植的15%临床显著有效率。
- 术后2年角膜上皮重建率为70%。
- 术后1年和2年视力改善率分别为50%和60%。
- 未观察到临床显著的移植相关不良事件。
关键数值与推荐
- 角膜上皮重建率是主要终点,术后1年成功率为60%(6/10眼),显著高于异体角膜缘移植的15%临床显著有效率。
- 角膜缘干细胞缺乏症严重程度按全球共识商定的分期方法判定,IA-C期眼评价为角膜上皮重建成功。
- 细胞片在移植前使用规定的运输标准进行评估,只有符合标准的细胞片才被使用。
临床怎么用
- 从健康眼获取角膜缘组织活检,分离角膜缘干细胞并在温度响应性培养表面培养,所有细胞片在药品生产质量管理规范级设施中按既定标准操作规程制备。
- 移植前去除覆盖角膜表面的结膜瘢痕组织,然后将细胞片移植到患者病变眼。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To confirm the efficacy and safety of Good Manufacturing Practice (GMP)-compliant autologous cultivated limbal epithelial cell sheets in government-controlled clinical trials that adhered to Good Clinical Practice stipulations for patients with unilateral limbal stem cell deficiency (LSCD). DESIGN: A prospective, multicenter, open-label, uncontrolled, single-arm clinical trial. PARTICIPANTS: Ten consecutive eyes of 10 patients with unilateral LSCD were followed for 2 years after surgery. Preoperative LSCD stage was IIB in 4 eyes and III in 6 eyes. METHODS: A limbal tissue biopsy was obtained from the healthy eye, after which limbal stem cells were dissociated and cultivated on temperature-responsive culture surfaces. All cell sheets were fabricated in a GMP-grade facility under established standard operating procedures. Cell sheets were evaluated using defined shipment criteria before transplantation, and only those that met the criteria were used. The cell sheet was transplanted onto each of the patients' diseased eye after removing the conjunctival scar tissue that covered the corneal surface. The severity of LSCD was determined according to a staging method agreed on by global consensus, with eyes evaluated as being in stages IA-C representing successful corneal epithelial reconstruction. Diagnosis and staging of LSCD were determined by the trial's Eligibility Judgment Committee and Effect Assessment Committee using slit-lamp photographs including fluorescein staining. Both committees comprised 2 or 3 third-party cornea specialists, who were provided with information anonymously and randomly. MAIN OUTCOME MEASURE: Corneal epithelial reconstruction rate was the primary end point. RESULTS: Corneal epithelial reconstruction was successful in 6 of 10 eyes (60%) 1 year postoperatively and was significantly higher than the 15% clinically significant efficacy rate achieved by allogeneic limbal transplantation. The reconstruction rate was 70% of eyes 2 years postoperatively. Additionally, improvements in visual acuity were noted in 50% and 60% of eyes at 1 and 2 years, respectively. No clinically significant transplantation-related adverse events were observed. CONCLUSIONS: The efficacy and safety of cultivated limbal epithelial cell sheet transplantation were thus confirmed, and the cell sheet, named "Nepic," is now approved as a cellular and tissue-based product in Japan. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
引用
- Oie Y, Sugita S, Yokokura S, et al. Clinical Trial of Autologous Cultivated Limbal Epithelial Cell Sheet Transplantation for Patients with Limbal Stem Cell Deficiency. Ophthalmology. 2023. PMID: 36736434. doi:10.1016/j.ophtha.2023.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。